Search

A leading IP lawyer in Palo Alto, California

“If A is success in life, then A equals x plus y plus z. Work is x; y is play; and z is keeping your mouth shut.” Albert Einstein

A spin-out from the University of Southampton, UK, has a new “scintillation detector” that it says can help stop radiological threats at airports and elsewhere.

New technology to repair the meniscus in the knee is under development at the University of Bristol, UK.

A new class of antibiotics, to tackle MRSA and other multi-resistant organisms, is in development by a spin-off from the University of Surrey, UK.

To change the physical characteristics of existing polymers for new market opportunities such as non-stick chewing gum.

A spin-out from the University of Surrey, England, is developing a new process to make silicon emit light – potentially cutting the cost of optical components.

Chewing gum, underwater robots and other technologies, at a UK investor showcase

The official Irish government report on the failed Media Lab Europe project has focused attention another industry-academic research partnerships – one involving Bell Labs and a consortium of eight Irish universities.

Sigma-Aldrich, a US-based Nasdaq-listed life science company, has agreed to license a gene delivery technology from Oxford BioMedica and will pay $5 million for a stake in the spin out from Oxford University.

Michael Kenward's roundup of new studies, reports and tools for the business of science

Scientists love to complicate things; and if you're not in the same field, or – worse – are in business or investment, then it's easy to get lost. Enter the Science|Business Quick Guides to some of the hottest fields of science and technology…

Energy: The Manchester “bobber” is using the power of ocean waves to find a lower-cost route to alternative energy.

Partnerships: An EU project aims to design road-hardened microchips in a fast-changing market.

Europe looks increasingly likely to follow America’s lead and require drug companies to test their products in children. But Europe's pharma lack the resources to carry out drug trials in children — so industry and patients will have to rely on the skills developed in academic centres.

Mary Lisbeth D'Amico's first fortnightly funding column reveals how coming out on top in a start-up talent show does not guarantee funding.